Cerus Corporation (CERS) News
Follow Cerus Corporation (CERS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
CERS Reports Fiscal Q3 Net Profit of -513万美元
Profit attributable to shareholders was -513万美元, up 61.84% year over year. Basic EPS was -0.03美元.
EQUITY | Nov 03, 2026, 05:49 AM UTC
L
Cerus Reports Q3 EPS of USD 0
EARNINGS | Nov 02, 2026, 09:30 PM UTC
M
Cerus Blood Safety System Meets Primary Endpoint in Late-Stage Study
EQUITY | Nov 02, 2026, 09:29 PM UTC
M
Cerus Reports Q3 Gross Profit of USD 30.3 Million
Cerus reported Q3 adjusted EBITDA of USD 5.7 million, versus an IBES estimate of USD 4 million.
EQUITY | Nov 02, 2026, 09:25 PM UTC
L
Cerus Reports Positive Topline Results From Phase 3 RedeS Trial
Cerus announced positive topline results from its Phase 3 RedeS trial of the INTERCEPT Blood System for red blood cells.
EQUITY | Nov 02, 2026, 09:25 PM UTC
M
Cerus Q3 Product Revenue Rises 10% to $57.7 Million
Cerus reported Q3 2026 product revenue of $57.7 million, up 10% from $52.7 million a year earlier. It reiterated 2026 product revenue guidance of $229 million–$231 million, up 11%–12% from 2025.
EQUITY | Nov 02, 2026, 09:22 PM UTC
M
Cerus Q3 2026 Net Loss Widens to $550,000
EQUITY | Nov 02, 2026, 09:21 PM UTC
M
Cerus Announces Third-Quarter 2026 Financial Results
Cerus said it reported financial results for the quarter ended September 30, 2026, and provided a business update.
EQUITY | Nov 02, 2026, 09:06 PM UTC
M
Cerus’ INTERCEPT for Red Blood Cells Meets Phase 3 Primary Endpoint
Cerus said its INTERCEPT system for red blood cells met the primary efficacy endpoint in a Phase 3 study.
EQUITY | Nov 02, 2026, 09:03 PM UTC
L
Freedom initiates CERS at Buy, sets $6.50 price target
Freedom initiates coverage of CERS with a Buy rating and a $6.50 price target.
EQUITY | Aug 20, 2026, 05:38 PM UTC
M
Cerus Shares Rise
ARK Investment buys 255K shares of Cerus
EQUITY | Aug 12, 2026, 12:20 AM UTC
H
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 300 points on Friday. Shares of Apple Inc (NASDAQ: AAPL ) fell sharply in pre-market trading after the company posted results for th
EARNINGS | Jul 31, 2026, 12:03 PM UTC
L
CERS Cerus raises 2026 product revenue guidance to $229M-$231M\n
CERS Cerus raises 2026 product revenue guidance to $229M-$231M\n
EARNINGS | Jul 30, 2026, 08:20 PM UTC
L
Cerus Raises FY2026 Sales Guidance from $227.000M-$231.000M to $229.000M-$231.000M vs $245.200M Est
Cerus (NASDAQ: CERS ) raises FY2026 sales outlook from $227.000 million-$231.000 million to $229.000 million-$231.000 million vs $245.200 million estimate.
EARNINGS | Jul 30, 2026, 08:02 PM UTC
L
CERS Cerus RESULTS: Q2, Q2 gross profit $29.5M, Q2 ADJ EBITDA $3M, Q2 operating expenses $37.3M, Q2 gross margin 51.4%
CERS Cerus RESULTS: Q2, Q2 gross profit $29.5M, Q2 ADJ EBITDA $3M, Q2 operating expenses $37.3M, Q2 gross margin 51.4%
EARNINGS | Jul 30, 2026, 08:01 PM UTC